T cell receptor (TCR)-engineered T cell therapy represents a cutting-edge approach in cancer immunotherapy, leveraging genetic modification to equip T cells with TCRs that specifically recognize tumor antigens presented on major histocompatibility complex (MHC) molecules. This evidence concerns the gene HLA-C and neoplasm.